Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rituximab for autoimmune haemophilia: a proposed treatment algorithm.

A Aggarwal1, R Grewal, R J Green

  • 1Washington Hospital Center, Washington, DC, USA. anita.aggarwal@medstar.net

Haemophilia : the Official Journal of the World Federation of Hemophilia
|January 22, 2005
PubMed
Summary

Rituximab effectively treats autoimmune haemophilia by normalizing Factor VIII levels. This monoclonal antibody offers a safe alternative, potentially reducing reliance on toxic immunosuppressants like prednisone.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First Experimental Limit on the Permanent Electric Dipole Moment of the Deuteron.

Physical review letters·2026
Same author

Real-world evidence reported for clinical efficacy evaluation in European Public Assessment Reports of authorised targeted therapies for solid malignancies: a comprehensive review (2018-2022).

ESMO real world data and digital oncology·2026
Same author

Evidence for the Collective Nature of Radial Flow in Pb+Pb Collisions with the ATLAS Detector.

Physical review letters·2026
Same author

Evidence for the Dimuon Decay of the Higgs Boson in pp Collisions with the ATLAS Detector.

Physical review letters·2025
Same author

ACE-RT, A Cloud-Based Tool for Remote Radiotherapy Contouring Support in Lower-Resourced Settings: A Pilot Evaluation.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

Outcomes and level of evidence in radiation therapy research and different categories of radiotherapy innovations: an ESTRO-VBRO bibliometrics analysis of the literature.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025

Area of Science:

  • Immunology
  • Hematology
  • Pharmacology

Background:

  • Autoimmune haemophilia is a rare bleeding disorder characterized by the development of inhibitors against Factor VIII.
  • Standard treatments involve immunosuppression with prednisone and cyclophosphamide, which can have significant toxicity.
  • Rituximab, an anti-CD20 monoclonal antibody, has shown promise in managing autoimmune conditions.

Observation:

  • Four additional patients with autoimmune haemophilia and inhibitor titres ranging from 5-60 BU to >200 BU were treated.
  • Patients received rituximab (4 or 8 weekly doses) with prednisone, and one received immunoglobulin.
  • Factor VIII levels normalized within 2-35 weeks across treated patients.

Findings:

  • Complete responses were observed, with two patients maintaining remission for 10 months.

Related Experiment Videos

  • Two patients relapsed (one with high initial titre >525 BU, one prednisone-dependent) but responded to re-treatment.
  • Rituximab appears safe and effective, potentially allowing reduced use of prednisone and cyclophosphamide.

    • Implications:

    • Rituximab is a valuable addition to immunosuppressive therapy for autoimmune haemophilia.
    • High-titre inhibitor patients may need multiple rituximab courses or cyclophosphamide.
    • An algorithm for rituximab incorporation into treatment protocols is proposed pending further studies.